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The  purpose  of  this  study  was  to investigate  the  in  vitro  effects  of  thalidomide  on  long-term  bone  marrow
cultures  from  patients  with  myelodysplastic  syndrome.  We  demonstrated  that  thalidomide  induced  an
increase  in granulocyte–macrophage  colony  forming  unit  numbers  and  in  IL-10  expression.  Thalidomide
also  promoted  a  slight  increase  in  IL-6,  IL-1  and  TNF-  expression  in  the stromal  layers.  The  numbers  of
erythroid  burst  forming  units,  the  apoptosis  rate  of hematopoietic  cells,  and  VEGF  and  TNF-  expressioneywords:
yelodysplastic syndromes
one  marrow microenvironment
halidomide
levels  in  culture  supernatants  were  not  modulated.  Our  results  indicate  a  participation  of thalidomide
upon  the  hematopoietic  microenvironment  of  patients  with  myelodysplastic  syndromes,  especially  in
the  up  regulation  of IL-10.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license.
ytokines
nterleukin-10
. Introduction
In myelodysplastic syndromes (MDS), blood cytopenias may
rise from intrinsic changes in the hematopoietic cells that increase
he susceptibility to apoptosis [1–5]. Furthermore, alterations in
he functional properties of marrow stroma that could contribute
o the defective development of hematopoietic cells have been
etected in a subset of patients [6–12]. The use of drugs that target
ematopoietic cells and the microenvironment, interfering with
he molecular mechanisms involved in cell growth and survival,
ould be effective in this disorder [6,8,13].
One possible explanation for the ineffective hematopoiesis in
DS may  be attributed, in part, to cytokine-mediated excessive
ntramedullary apoptosis of hematopoietic cells. Tumor necrosis
actor alpha (TNF-) and interleukin 1-beta (IL1-) appear to be
mportant proapoptotic cytokines [14–16]. Another possible mech-
nism involved in the pathophysiology of MDS  is neo-angiogenesis,
 phenomenon, which appears to be present in a variety of human
ancers and is modulated by several cytokines and growth factors,
ncluding vascular endothelial growth factor (VEGF) and TNF-
17,18]. Interleukin 10 (IL-10), though not yet fully characterized in
DS, inhibits spontaneous myeloid blast proliferation and colony
∗ Corresponding author at: Hematology and Hemotherapy Center, University of
ampinas, Rua Carlos Chagas 480, 6198, Campinas, SP, Brazil. Tel.: +55 19 35218734;
ax:  +55 19 32891089.
E-mail address: marilazarini@gmail.com (M.  Lazarini).
145-2126/© 2011 Elsevier Ltd. 
oi:10.1016/j.leukres.2011.03.027
Open access under the Elsevier OA license.formation and decreases the secretion of other cytokines in vitro
[19].
Thalidomide is a drug with anti-angiogenic, immunomodu-
latory and anti-cytokine activities, therefore it is still used in
myelodysplastic syndromes [20–24]. Regardless of its various
properties, the mechanisms of action of this drug have not yet
been fully elucidated. Long-term bone marrow cultures (LTBMCs)
techniques represent a functional model of the hematopoietic
microenvironment, with a layer of adherent stromal cells (includ-
ing macrophages, endothelial cells and adipocytes) supporting the
proliferation and differentiation of progenitor cells [25,26]. There-
fore, they have long been used to assess patterns of hematopoiesis
and determine possible pathogenetic mechanisms underlying MDS
[10,25,27,28]. In LTBMCs from MDS  patients, a deﬁciency in the
maintenance and growth of hematopoietic cells and abnormalities
of MDS  stromal compartment have been previously reported [10].
The purpose of the present study was  to investigate the mechanism
of action of thalidomide on LTBMCs from MDS  patients through the
examination of the effects of this drug upon the growth and dif-
ferentiation of hematopoietic progenitors, apoptosis and cytokines
expression.
2. Material and methods2.1.  Bone marrow samples
Bone  marrow aspirates were obtained from 6 patients with a diagnosis of
the  novo MDS, classiﬁed as follows: 5 refractory anemia (RA), 1 RA with ringed
sideroblasts (RARS), according to the French–American–British (FAB) classiﬁca-
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ion.  According to the World Health Organization (WHO) 2008 classiﬁcation, these
atients were classiﬁed as 5 refractory cytopenia with multilineage dysplasia
RCMD), 1 refractory anemia with ring sideroblasts (RARS). The samples were
btained at the time of diagnosis and none of the patients had received any cytotoxic
rugs or growth factors for MDS  treatment. All of the patients that contributed to
his  study provided informed written consent and the National Ethical Committee
oard approved the study. Patient characteristics are shown in Table 1.
.2. Primary long-term cultures and thalidomide treatment
Long-term bone marrow cultures were established according to Gartner and
aplan [25] with minor modiﬁcations. Mononuclear cells (MNCs) from bone mar-
ow  samples were separated on Ficoll Hypaque density gradients (1.077) at 400 g for
0  min. 107 cells were cultured into 10 mL  of Iscove’s Dulbecco’s medium (IMDM)
ontaining l-glutamine and 100 U/mL penicillin/streptomycin, supplemented with
etal calf serum (12.5% v/v), horse serum (12.5% v/v) and 10 M hydrocortisone. On
he  ﬁrst day, the cultures were treated with 10 M of thalidomide or 0.01% dimethyl-
ulphoxide (DMSO) (control cultures) and maintained for 4 weeks at 37 ◦C in an
tmosphere of 5% CO2. At weekly intervals, cultures were fed by demi-depopulation
nd the drug was reinstated (ﬁnal concentration of 10 M).
Thalidomide was purchased from Calbiochem, San Diego, CA; DMSO from Sigma,
t  Louis, MO.  The drug was  dissolved in DMSO to prepare a stock concentration of
0  mM.  This stock solution was stored at −80 ◦C and diluted in culture medium prior
o  use.
.3. Clonogenic assays
Hematopoietic activity in primary long-term cultures treated or not with
halidomide was assessed weekly in supernatants removed during demi-feeding.
rieﬂy, 105 cells were seeded onto 35-mm plastic culture dishes in 1 mL  methylcel-
ulose media in IMDM containing fetal calf serum, rh SCF, rh GM-CSF, rh IL-3, serum
lbumin bovine, 2-mercaptoetanol e l-glutamine (MethoCult® GF H4534, Stem-
ell  Technologies, Vancouver, Canada), supplemented with 2 UI/mL of erytropoietin
Janssen-Cilag, Athens, Greece). After 14 days of incubation at 37 ◦C under 5% CO2
nd high humidity, the number of granulocyte–macrophage colony forming units
CFU-GMs) and burst forming unit–erythroids (BFU-Es) was assessed. CFU-GM was
eﬁned as a cluster containing 20 or more granulocytes and macrophages, whereas
rythroid colonies were scored as red clones exceeding 50 cells.
.4.  Assessment of apoptosis by annexin-V binding and ﬂow cytometry
Apoptosis was analyzed in part of the cells collected on the supernatant during
emi-feeding at the third week. Apoptosis was assessed by ﬂow cytometry using
nnexin-V binding. Cells were washed in PBS and then resuspended in annexin-V
inding buffer (BD Pharmingen, San Diego, CA, USA); 5 × 105 cells were incubated
ith ﬂuorescein isocyanate (FITC)-labelled recombinant annexin-V (1 L/mL) for
5  min, room temperature, in the dark. Samples were then diluted in binding buffer
nd analyzed by ﬂow cytometry (FACSCalibur; Becton Dickinson, San Jose, CA, USA)
ithin 1 h. Propidium iodide (PI) (1 L/mL) was added 10 min  before ﬂow cytometry
nalysis. A total of 10,000 events were analyzed. Cells labelled with FITC and negative
or PI were considered apoptotic.
.5. Enzyme-liked immunoabsorbent assays
Levels of VEGF and TNF-were evaluated in the supernatant of LTBMCs collected
t  weekly intervals. The levels of the two cytokines were determined by enzyme-like
mmunoabsorbent assay (ELISA), using commercial kits from Biosource (Invitrogen,
alifornia, USA). All assays were performed in triplicate according to the manufac-
urer’s instructions. The limit of detection of each ELISA kit was  as follows: VEGF,
5.0  pg/mL; TNF-, <0.09 pg/mL.
.6. Collection of adherent layers
After 4 weeks of culture, the medium containing non-adherent hematopoi-
tic cells was removed and the cells from the adherent layer were washed with
trength three times with 10 mL  of cold PBS, trypsinized (TryPLE Express; Invitro-
en,  Carlsbad, CA) and submitted to RNA extraction. In order to conﬁrm the absence
f  contamination with precursor hematopoietic cells, analysis of the cell surface of
ome molecules was performed using ﬂow cytometry in two  samples. Brieﬂy, a total
f  2 × 105 harvested cells were washed and suspended in 0.5 mL  of PBS, and incu-
ated for 30 min  on ice in the dark with two  of the following monoclonal antibodies:
nti-CD14-FITC (Caltag Laboratories, Burlingame, CA), anti-CD34-PE (BD Pharmin-
en, San Diego, CA, USA), anti-CD3-FITC (Glostrup, Denmark), and anti-CD19-PE
Glostrup, Denmark). Cells incubated with their corresponding isotype control were
lso included. The labelled cells were analyzed on a FACSCalibur (Becton Dickinson,
an Jose, CA, USA) by collecting 10,000 events. Our analyses showed expression of
ew CD14-positive cells (5%), consistent with the presence of some macrophages;
bsence of lymphocytes, since no CD3-positive cells were observed; very low per-
entage of CD19-positive cells (approximately 2.5%); and no expression of CD34
ells. Ta
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Table 2
Primers used for quantitative RT-PCR analysis. Sequences of primers used for quantitative RT-PCR assays. Bp = base pairs.
Gene Primers (5′ 3′) Fragment length
IL-10 Sense GCTGAGAACCAAGACCCAGA 96 bp
Antisense AAATCGATGACAGCGCCGT
IL-6 Sense GGTACATCCTCGACGGCATCT 61 bp
Antisense GTGCCTCTTTGCTGCTTTCAC
IL-1 Sense CTTTGAAGCTGATGGCCCTAAA 82 bp
Antisense AGTGGTGGTCGGAGATTCGT
TNF- Sense CCCAGGCAGTCAGTAAGTGTC 56 bp
Antisense AGCTGCCCCTCAGCTTGA
IFN- Sense TGTAGCGGATAATGGAACTCTTTTC 66 bp
Antisense AATTTGGCTCTGCATTATTT
ABL Sense TGGAGATAACACTCTAAGCA 105 bp
Antisense GATGTAGTTGCTTGGGACCC
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Fig. 1. Effects of thalidomide on myeloid colony formation during long-term bone
marrow cultures of MDS  patients. Mononuclear cells from bone marrow samples
were cultured in appropriate medium with the addition of DMSO 0.01% (control-
Ctrl) or 10 M of thalidomide (Thal) at weekly intervals, for 4 weeks. The number.7. Quantitative RT-PCR analysis
The mRNA expression of the cytokines IL-10, IL-6, IL-1, TNF- and INF-were
erformed in the adherent layers by quantitative RT-PCR assays (qRT-PCR). RNA
as  isolated from cells of the adherent layers using Trizol Life Reagents (Invitro-
en, Carlsbad, CA). For reverse transcription (RT), 1 g of total RNA per sample was
sed as a template for cDNA synthesis using Superscript III (Invitrogen, Carlsbad,
A) following the manufacturer’s guidelines. Real-time detection of ampliﬁcation
as  performed in 7300 Real-Time PCR System (Applied Biosystems) using Power
ybrGreen PCR Master Mix  (Applied Biosystems). Each gene was  analyzed in parallel
ith the Abelson (ABL) housekeeping gene. The absolute level of IL-10, IL-1, IL-6,
NF- and INF- was  then normalized to the ABL mRNA content. The sequences of
he  primers used for the ampliﬁcation are described in Table 2. The relative quan-
iﬁcation value of gene expression was calculated using the equation, 2−CT [29].
ll samples were run in triplicate. Gene expression on control cultures received the
rbitrary score of 1 point. Changes caused by thalidomide were expressed as fold
hange of the baseline value.
.8. Statistics
Wilcoxon matched pairs test was used to compare CFU-GM and BFU-E num-
ers, apoptosis rate and VEGF expression levels among control and treated cultures.
he Student’s t-test for paired samples was used to deﬁne differences among con-
rol  and treated cultures for IL-10, IL-6, IL-1 and TNF- expression in stromal
ayers. Statistical comparison of the biological parameters on the same culture,
ver the weeks, was  carried out using Kruskal–Wallis test. Results are presented
s  mean ± standard deviation (SD). A p value of ≤0.05 was considered statistically
igniﬁcant.
. Results
.1. In vitro hematopoesis or clonogenic progenitor cell assays
We ﬁrst tested the effect of thalidomide on
ranulocyte–macrophage and erythroid progenitor cell growth
sing colony-forming assays. CFU-GM and BFU-E were counted, at
eekly intervals, and were detected between 5 and 4 BMNCs out
f 6 MDS  patients submitted to LTBMCs. Thalidomide treatment
esulted in a signiﬁcant increase in CFU-GM numbers at the second
nd fourth week of culture (Fig. 1) and, although not statistically
igniﬁcant, in a small increase in CFU-GM numbers at the third
eek. The mean number (±SD) of total CFU-GM (n = 5) obtained
rom control vs. thalidomide cultures, at the end of the ﬁrst,
econd, third and fourth week, were 5453 ± 2630 vs. 5373 ± 2800,
948 ± 995 vs. 2343 ± 1242, 705 ± 335 vs. 747 ± 339 and 460 ± 318
s. 537 ± 333, respectively. BFU-E numbers were not modiﬁed by
halidomide treatment. The mean number (±SD) of total BFU-E
n = 4) obtained from control vs. thalidomide cultures, at the end
f the ﬁrst, second, third and fourth week, were 1707 ± 2814 vs.
467 ± 2143, 408 ± 660 vs. 530 ± 880, 56 ±91 vs. 62 ± 102, 5 ± 5 vs.
2 ± 12, respectively.of granulocyte–macrophage colony forming units (CFU-GM) was assessed in super-
natants removed during demi-feeding at the second and fourth weeks of culture.
Results are shown as means (±SD) from 5 patients.
3.2. Effects of thalidomide on apoptosis
We evaluated the annexin-V positive cells in the supernatants of
conﬂuent LTBMCs from MDS  patients submitted or not to thalido-
mide exposure in vitro. At the third week of culture, the rate of
apoptosis was not affected by thalidomide treatment, 18.5 ± 11.9%
for control and 15.7 ± 9.5% for thalidomide cultures, p > 0.05 (Fig. 2).
None of the cells were positive for PI. At the fourth week of culture,
the number of cells in the supernatant was  not sufﬁcient to evaluate
apoptosis.
3.3. Levels of VEGF and TNF-  ˛ in LTBMCs supernatant
When analysing cytokines levels over the weeks, inde-
pendently of thalidomide exposure, we  found that VEGF
levels increased weekly in LTBMCs: 113 ± 112.4, 604.3 ± 463.6,
1084.1 ± 363.8, 1211.47 ± 189.8 for control cultures (n = 6);
p = 0.001 (Kruskal–Wallis test) and 105.3 ± 105.6, 597.35 ± 468.4,
1045.4 ± 303.1, 1297.7 ± 195.8 for thalidomide cultures (n = 6);
p < 0.001 (Kruskal–Wallis test); at the ﬁrst, second, third and fourth
week, respectively. TNF- was detected in the supernatant of only
two  cultures. In contrast, although not statistically signiﬁcant, TNF-
 levels decreased over the weeks, both in control and thalidomide
treated cultures. At the end of the ﬁrst, second, third and fourth
M. Lazarini et al. / Leukemia Research 35 (2011) 1102– 1107 1105
Fig. 2. Effects of thalidomide on apoptosis during long-term bone marrow cul-
tures of MDS  patients. Mononuclear cells from bone marrow samples were cultured
in  appropriate medium with the addition of DMSO 0.01% (Control) or 10 M of
thalidomide (thalidomide) at weekly intervals, for 4 weeks. On the third week of
culture, apoptosis was analyzed in part of the cells collected on the supernatant
during demi-feeding. Apoptosis was measured as the sum of all annexin-V positive
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Fig. 3. Effects of thalidomide on expression of VEGF and TNF- protein expres-
sion in culture supernatant during long-term bone marrow cultures of MDS
patients. Mononuclear cells from bone marrow samples were cultured in appropri-
ate  medium with the addition of DMSO 0.01% (Control-Ctrl) or 10 M of thalidomide
(Thal) at weekly intervals, for 4 weeks. The expression of VEGF (A) and TNF- (B)
protein was assessed weekly in supernatants removed during demi-feeding, by an
enzyme-linked immunosorbent assay (ELISA). The expression of VEGF and TNF-
did not differ signiﬁcantly between control and thalidomide cultures. Results are
shown as means (±SD) of protein concentration from 6 patients for VEGF and from
2  patients for TNF-.
Fig. 4. Effects of thalidomide on expression of IL-10, IL-6, IL-1 and TNF- mRNA in
stromal layers during long-term bone marrow cultures of MDS patients. Mononu-
clear cells from bone marrow samples were cultured in appropriate medium with
the  addition of DMSO 0.01% (Control-Ctrl) or 10 M of thalidomide (Thal) at weekly
intervals, for 4 weeks. On the fourth week, the mRNA levels of different cytokines in
the stromal layers were quantiﬁed by qRT-PCR. Gene expression on control culturesnd PI-negative cells. The percentage of apoptotic cells did not change signiﬁcantly
etween control and thalidomide cultures. Results are shown as means (±SD) from
 patients.
eek, respectively, TNF- levels were 1.44 ± 1.57, 1.39 ± 1.77,
.22 ± 0.30, 0.03 ± 0.04 for control cultures (n = 2), p > 0.05; and
.77 ± 1.78, 1.87 ± 2.41, 0.34 ± 0.37, 0.08 ± 0.01 for thalidomide cul-
ures (n = 2), p > 0.05 (Fig. 3).
Regarding the effects of thalidomide, VEGF levels in the super-
atants of MDS-LTBMCs submitted to thalidomide exposure were
ot signiﬁcantly different from control cultures (Fig. 3A), however,
halidomide treatment resulted in a tendency to increase TNF-
evels in the supernatants of thalidomide cultures compared to
ontrol cultures, in all weeks (Fig. 3B).
.4. Cytokines mRNA expression in stromal layers
Interleukin-10, IL-6, IL-1, TNF- and INF- mRNA expression
ere examined by qRT-PCR in the stromal layers of LTMBCs, on
he fourth week. Gene expression on control cultures received
he arbitrary score of 1 point. Changes caused by thalidomide
ere expressed as the fold change of the baseline value (Fig. 4).
 pronounced up regulation of IL-10 expression was  observed in
tromal layers from the cultures submitted to thalidomide expo-
ure compared to control cultures (increased by 3-fold, p = 0.03,
aired t-test). The expression levels of the other cytokines showed
 tendency to increase due to thalidomide treatment, however, this
ncrease was not statistically signiﬁcant: increased by 1.24-fold for
L-6, 1.15-fold for IL-1 and 1.93-fold for TNF- mRNA expression,
 > 0.05. INF- expression was not detected in the adherent cells
rom any of the cultures.
. Discussion
Previous studies described functional abnormalities of stromal
ells in MDS, thus drugs targeting hematopoietic cells and also
he microenvironment could be of interest for treatment [4,6].
halidomide has been described as effective in improving anemia
nd, less frequently, other cytopenias in patients with low-risk
DS  [22,24]. We  herein reported the results obtained with pri-
ary human BMNC cells from six low-risk MDS  patients, exposed,
n vitro, to 10 M of thalidomide. To the best of our knowledge,
his is the ﬁrst time that LTBMCs from MDS  patients were used to
nalyze the effects of thalidomide.
Regarding cytokine gene expression in stromal layers of
TBMCs, an increase in IL-10 was observed following 10 M
received the arbitrary score of 1 point. The expression of IL-10 was signiﬁcantly
increased with thalidomide treatment. Results are shown as means (±SD) of fold
change of stimulation compared to control value from 6 patients.
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halidomide treatment. LTMBCs from two patients were also
reated with the dose of 100 M and a further increment in IL-
0 expression was observed (data not shown), suggesting that the
p regulation of this cytokine may  be dose dependent. IL-10 is a
leiotropic cytokine, which is produced by a variety of cells, includ-
ng T-cells and macrophages, and inhibits the expression of IL-1,
L-6 and TNF- in activated macrophages most likely at the tran-
criptional level [30,31].  IL-10 has been described to irreversibly
nhibit spontaneous myeloid blast proliferation and decrease the
ecretion of IL-1, IL-1, TNF-, granulocyte–macrophage colony-
timulating factor and IL-6, depending on which exogenous growth
actors are present [19,32]. We  observed that thalidomide treat-
ent results in an increase in IL-10 expression in stromal layers
rom MDS  LTBMCs, with no decrease in the expression of IL-6,
L-1, TNF-. Hence, the induction of IL-10 expression in stro-
al  layers by thalidomide suggests a beneﬁcial effect of this drug
elaying disease progression, by mechanisms independent of the
ecrease of these cytokines indicating a participation of thalido-
ide on the hematopoietic microenvironment cells from MDS
atients.
Although thalidomide has been reported to have anti-TNF-  and
nti-angiogenic effects [33,34], our results demonstrated that VEGF
evels were not signiﬁcantly modulated by thalidomide exposure
nd although not statistically different, thalidomide was  able to
nduce a small increase in TNF- expression, in both mRNA and
rotein levels. Interesting, a signiﬁcant increase in VEGF levels
as observed by Invernizzi et al. [35], whereas Zorat et al. [21]
bserved an unchanged expression of VEGF and TNF- in MDS
atients treated in vivo with thalidomide. Furthermore, no sig-
iﬁcant modulation of TNF- and VEGF was observed in CD34+
ells from MDS  del(5q) patients treated in vivo with lenalidomide
13]. Taken together, these results conﬁrm that thalidomide effects
ay vary depending on the tissue considered and indicate that,
n MDS, VEGF and TNF- may  not be signiﬁcantly modulated by
halidomide treatment or its derivatives. Therefore, the biological
eneﬁt of these drugs may  be explained by the modulation of other
ytokines.
In LTBMCs of MDS  patients, we observed an increase in VEGF
nd a decrease in TNF- levels over the weeks in a time-dependent
anner in the supernatants of cultures, independent of thalido-
ide exposure. This result might indicate the role of LTBMC stromal
ayers in producing VEGF and the role of supernatant hematopoietic
rogenitor cells in producing TNF-, as there was a predominance
f hematopoietic cells in the supernatant of LTBMCs during the ﬁrst
eeks of culture, whereas there were a greater number of cells from
tromal layers during the later weeks.
Thalidomide treatment resulted in an increase in the CFU-GM
olony growth. These data indicate that thalidomide may  improve
he ability of stromal layers to support haematopoiesis. BFU-E
umber did not change with thalidomide treatment, even when
halidomide dose was increased up to 100 M (data not shown).
erbajinai et al. [36] had previously described that thalidomide
xhibited different effects at distinct stages of erythroid cell devel-
pment, as an inhibition of CFU-E colonies on day 7 and an increased
n the number of BFU-E colonies on day 14 of the culture of CD34+
DS  cells exposed to 100 M of thalidomide. Furthermore, in
DS  del (5q), treatment with lenalidomide in vivo signiﬁcantly
mproved the clonogenic potential of bone marrow erythroid and
yeloid colony-forming cells [13]. Although different methods and
pproaches were used by us and others, these studies indicate some
mprovement in haematopoiesis upon thalidomide treatment.
It has already been described that in normal haematopoietic
ells, IL-10 induced an increase in CFU-GM, in a dose dependent
anner, suggesting a potential use of this cytokine in the expan-
ion of myeloid progenitors [37]. Therefore, in the present study,
he up-regulation of IL-10 expression in stromal layers treatedarch 35 (2011) 1102– 1107
with thalidomide may  have led to hematopoiesis improvement,
observed through the increase in CFU-GM numbers.
Thalidomide and the immunomodulatory derivative (IMiD) CC-
4047 effects in vitro, in normal CD34-positive cells, have been
previously described (Koh et al. [38]) and corroborate our ﬁndings,
showing an increase in the number of CFU-GM after 14 days of
culture. Moreover, regarding cytokines expression, the aforemen-
tioned authors also reported an up-regulation of IL-10 expression
in normal CD34-positive cells upon thalidomide or IMiD CC-4047
treatment, whereas no modulation of TNF- or IL-1 expression
was  observed [38].
Thalidomide is a drug still used for MDS  treatment in devel-
oping countries and its indication in multiple myeloma and other
haematological malignancies has gained importance in the recent
years, highlighting the importance of studies aiming to elucidate
the biological effects of this drug in haematological malignancies.
The complexity of MDS  populations and the difﬁculty in obtaining
successful bone marrow cells from these patients renders the study
of the effects of thalidomide on this disease difﬁcult. Many authors
have tested different approaches in the attempt to better under-
stand the precise mechanism of action of this drug on MDS  and our
results indicate that thalidomide increases CFU-GM number and IL-
10 expression in vitro in MDS  LTBMCs. In this context, although the
biological relevance of these ﬁndings remains to be elucidated, our
data are most likely to be important in understanding the biology
of MDS.
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